Recent analyst commentary on Inspire Medical Systems (INSP) has turned more cautious, highlighting reimbursement coding challenges and the need for clearer catalysts. This shift has brought renewed attention to the stock’s risk profile.
See our latest analysis for Inspire Medical Systems.
The recent caution from analysts comes after a period where the stock’s 30 day share price return is down 22.15% and the year to date share price return is down 52.49%, while the 1 year total shareholder return is down 69.39%. This signals that momentum has been fading despite short bursts of strength, such as the 7 day share price return of 4.81%.
If analyst sentiment and reimbursement risks have you rethinking exposure to single healthcare names, it may be worth broadening your watchlist with 34 healthcare AI stocks
With Inspire Medical Systems now trading at a discount of about 16% to the average analyst price target and 15% to an intrinsic estimate, you have to ask yourself: is this weakness a genuine opportunity, or is the market already bracing for slower growth?
Most Popular Narrative: 44.8% Undervalued
Inspire Medical Systems last closed at $43.84, compared with a widely followed fair value narrative of $79.42, which frames the recent share price slide very differently from the headline returns.
The recent delay in transitioning centers to the Inspire V next-generation system, including slower onboarding, delayed SleepSync implementation, and the Medicare billing update, are transitory issues; as these barriers resolve (with Medicare billing now live and most centers expected to complete onboarding by end of Q3), procedure volumes and revenue growth are positioned to reaccelerate in 2026 as pent-up demand is realized.
Curious what kind of revenue path, earnings profile and valuation multiple underpin a fair value almost twice the last close, even with lower growth baked in?
Result: Fair Value of $79.42 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this narrative still leans heavily on smooth Inspire V adoption and supportive reimbursement decisions, both of which could yet disappoint and reset expectations again.
Find out about the key risks to this Inspire Medical Systems narrative.
Next Steps
Cautious about the mixed sentiment running through this story but do not want to sit on the sidelines too long? Put the recent moves in context by weighing both sides of the argument with 3 key rewards and 1 important warning sign
Looking for more investment ideas?
Do not stop your research with a single stock. Broader ideas can help you spread risk and uncover opportunities that might not be on your radar yet.
- Pinpoint potential bargains by scanning through 48 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect them.
- Strengthen your focus on capital preservation by checking out 69 resilient stocks with low risk scores that score well on resilience and downside protection.
- Get ahead of the crowd by reviewing a screener containing 21 high quality undiscovered gems that the wider market may not be paying close attention to yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com